Prothena Current Ratio 2011-2022 | PRTA
Prothena current ratio from 2011 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Prothena Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.53B |
$0.05B |
10.37 |
| 2022-06-30 |
$0.52B |
$0.04B |
13.00 |
| 2022-03-31 |
$0.56B |
$0.04B |
15.22 |
| 2021-12-31 |
$0.59B |
$0.03B |
17.48 |
| 2021-09-30 |
$0.61B |
$0.03B |
20.81 |
| 2021-06-30 |
$0.41B |
$0.05B |
7.74 |
| 2021-03-31 |
$0.35B |
$0.02B |
15.02 |
| 2020-12-31 |
$0.30B |
$0.03B |
11.58 |
| 2020-09-30 |
$0.32B |
$0.02B |
14.75 |
| 2020-06-30 |
$0.34B |
$0.02B |
18.40 |
| 2020-03-31 |
$0.36B |
$0.02B |
21.05 |
| 2019-12-31 |
$0.38B |
$0.02B |
21.36 |
| 2019-09-30 |
$0.41B |
$0.03B |
12.88 |
| 2019-06-30 |
$0.42B |
$0.03B |
14.95 |
| 2019-03-31 |
$0.42B |
$0.02B |
27.85 |
| 2018-12-31 |
$0.43B |
$0.02B |
28.90 |
| 2018-09-30 |
$0.46B |
$0.02B |
19.34 |
| 2018-06-30 |
$0.49B |
$0.05B |
10.71 |
| 2018-03-31 |
$0.54B |
$0.04B |
15.11 |
| 2017-12-31 |
$0.43B |
$0.04B |
11.41 |
| 2017-09-30 |
$0.47B |
$0.04B |
11.95 |
| 2017-06-30 |
$0.51B |
$0.04B |
12.92 |
| 2017-03-31 |
$0.51B |
$0.03B |
15.27 |
| 2016-12-31 |
$0.39B |
$0.04B |
9.53 |
| 2016-09-30 |
$0.42B |
$0.04B |
11.26 |
| 2016-06-30 |
$0.45B |
$0.03B |
13.47 |
| 2016-03-31 |
$0.48B |
$0.02B |
20.75 |
| 2015-12-31 |
$0.38B |
$0.02B |
16.99 |
| 2015-09-30 |
$0.39B |
$0.02B |
21.21 |
| 2015-06-30 |
$0.41B |
$0.01B |
30.19 |
| 2015-03-31 |
$0.28B |
$0.01B |
29.80 |
| 2014-12-31 |
$0.30B |
$0.01B |
24.85 |
| 2014-09-30 |
$0.31B |
$0.01B |
30.97 |
| 2014-06-30 |
$0.31B |
$0.01B |
27.14 |
| 2014-03-31 |
$0.20B |
$0.01B |
22.27 |
| 2013-12-31 |
$0.18B |
$0.01B |
24.07 |
| 2013-09-30 |
$0.10B |
$0.01B |
13.34 |
| 2013-06-30 |
$0.11B |
$0.01B |
12.51 |
| 2013-03-31 |
$0.12B |
$0.01B |
23.75 |
| 2012-12-31 |
$0.13B |
$0.00B |
72.16 |
| 2012-09-30 |
$0.00B |
|
0.00 |
| 2012-06-30 |
$0.00B |
|
0.00 |
| 2012-03-31 |
$0.00B |
|
0.00 |
| 2011-12-31 |
$0.00B |
$0.01B |
0.01 |
| 2010-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.659B |
$0.201B |
|
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
|
